At Interpace Diagnostics, a business unit of Interpace Biosciences, we leverage the latest technology to develop and commercialize novel molecular diagnostic tests. Our tests are designed to detect genetic alterations that are associated with gastrointestinal, endocrine and lung cancer existence or risk, which are principally focused on early detection and identification of high potential progression to cancer.
When managing thyroid nodules, physicians need to distinguish potentially malignant nodules from those with benign disease to limit unnecessary surgery. Visit a CME activity on myCME, an educational website for clinicians, to learn more about commercially available molecular tests for indeterminate thyroid nodules.
Learn MoreThyGenNEXT® is an oncogenic mutation panel that helps identify malignant thyroid nodules.
ThyGenXLearn MoreThyraMIR® is a proprietary microRNA gene expression assay that helps to classify the risk of cancer in thyroid nodules.
ThyraMIRLearn MorePancraGEN® is a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess the risk of pancreaticobiliary cancers using our proprietary PathFinderTG® platform. Also known as "Integrated Molecular Pathology", PancraGEN® combines the insights that come from first line testing such as serum markers (Amylase, CEA), imaging, and cytology with those derived from measuring DNA quantity, quality, and tumor suppressor genes (LOH) that are highly correlated to pancreatic cancer.
PancraGENLearn MoreRespriDXTM is a molecular test that helps physicians differentiate metastatic or recurrent lung cancer from the presence of a newly formed primary lung cancer. RespriDXTM also utilizes our PathFinderTG ® platform to compare the genomic fingerprint of two or more sites where lung cancer tumors are present.
RespriDXLearn MoreBarreGen® is an esophageal cancer risk classifier for Barrett's Esophagus that predicts which patients with Barrett's Esophagus will progress to Esophageal cancer over time. BarreGen® also utilizes our PathFinderTG® platform.
BarreGenLearn MoreCOVIANT™ is a blood test that determines the presence of IgG antibodies to SARS-CoV-2, the virus that causes COVID-19. A high level of IgG is generally regarded as indicating that a person has been exposed to the infectious agent that triggered the immune response. Understanding the long-term immunity offered by IgG antibodies to COVID-19 disease, however, is limited.
COVIANTLearn More